These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2701727)

  • 21. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():63. PubMed ID: 2496883
    [No Abstract]   [Full Text] [Related]  

  • 22. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
    Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
    Blood; 1992 Feb; 79(4):997-1002. PubMed ID: 1371081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
    Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
    Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
    Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
    Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of alpha-interferons in chronic myelogenous leukaemia.
    Talpaz M
    Br J Clin Pract Suppl; 1988 Mar; 62():13-5. PubMed ID: 3145008
    [No Abstract]   [Full Text] [Related]  

  • 28. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
    Bartsch HH; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel GA
    Int J Cancer; 1989 Feb; 43(2):235-40. PubMed ID: 2521842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.
    Talpaz M; Trujillo JM; Hittelman WN; Keating MJ; Gutterman JU
    Br J Haematol; 1985 Aug; 60(4):619-24. PubMed ID: 3861194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
    Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
    Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The treatment of chronic myeloid leukemia in chronic phase with interferons].
    Guilhot F
    Pathol Biol (Paris); 1988 Dec; 36(10):1179-81. PubMed ID: 3070457
    [No Abstract]   [Full Text] [Related]  

  • 32. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
    Cancer; 1992 Jan; 69(2):410-2. PubMed ID: 1370212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
    Strozha I; Petukhov V; Bondare D; Feldmane G; Duks A; Teilane I; Medne I; Mauritsas M; Grinberga L
    Ter Arkh; 1993; 65(10):62-6. PubMed ID: 8296238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
    Claxton D; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU; Talpaz M
    Acta Haematol; 1990; 83(3):149-51. PubMed ID: 2109455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Juvenile chronic myeloid leukaemia and alpha-interferon.
    Aricò M; Nespoli L; Caselli D; Bonetti F; Porta FA; Burgio GR
    Eur J Pediatr; 1989 Jan; 148(4):379-80. PubMed ID: 2707286
    [No Abstract]   [Full Text] [Related]  

  • 36. CML: new biologic therapies, endpoints and questions.
    Martin A; Cheson BD
    Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
    [No Abstract]   [Full Text] [Related]  

  • 37. Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
    Wahlin A; Holm J; Engman K
    Acta Oncol; 1991; 30(5):611-5. PubMed ID: 1892679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
    Schilling PJ; Kurzrock R; Kantarjian H; Gutterman JU; Talpaz M
    Cancer; 1991 Oct; 68(7):1536-7. PubMed ID: 1893353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon and chronic myelogenous leukaemia.
    Lauta VM
    Med Oncol; 1995 Mar; 12(1):41-6. PubMed ID: 8542246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotherapy of chronic myelogenous leukemia with interferon.
    Ozer H
    Semin Oncol; 1988 Oct; 15(5 Suppl 5):14-20. PubMed ID: 2461592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.